Abstract
Background
NCCN and Japanese clinical guidelines for the treatment of biliary tract cancer (BTC) addressed gemcitabine–cisplatin combination (GC) as first-line chemotherapy for patients with advanced BTC ineligible for surgery in 2013. However, gemcitabine–S1 combination therapy (GS) has been widely used as first-line treatment in Japan because Japanese social insurance coverage of S-1 for BTC was approved prior to that of cisplatin.
Aim
To elucidate the efficacy and tolerability of GC as second-line chemotherapy for patients with unresectable BTC after failure of GS.
Patients and methods
Between September 2008 and August 2011, patients with unresectable BTC who provided informed consent and received GC comprising gemcitabine at 1000 mg/m2 and cisplatin at 20 mg/m2 given on days 1 and 8 in a 3-week cycle after failure of GS were included in the present study. Clinical data from these patients were collected prospectively. Primary endpoints were overall survival and time to progression (TTP). Secondary endpoints were response and tolerability.
Results
Twenty-seven patients were analyzed. Median survival time (MST) and TTP from the beginning of second-line treatment were 6.5 and 3.3 months, respectively, whereas MST from the commencement of first-line therapy was 12.06 months. One patient showed partial response, 16 had stable disease and 10 experienced disease progression. As a result, disease control rate was 63.0%. In total, 119 courses (median, 4; range, 1–15) were administered. Discontinuation of GC due to drug toxicities was not observed.
Conclusion
Although some issues remain to be clarified, mainly due to the small sample size, this single-institution experience with GC as second-line treatment after failure of GS showed acceptable outcomes and good tolerability.
Similar content being viewed by others
References
Gores GJ (2003) Cholangiocarcinoma: current concepts and insight. Hepatology 37:961–969
Rajagopalan V, Daines WP, Grossbard ML et al (2004) Gallbladder and biliary tract carcinoma: a comprehensive up date, Part 1. Oncology 18:889–896
Matsuda T, Marugame T (2007) International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from cancer incidence in five continents. Jpn J Clin Oncol 37:74–75
Randi G, Malvezzi M, Levi F et al (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146–159
Leonard GD, O’Reilly EM (2005) Biliary tract cancer: current concepts and controversies. Expert Opin Pharmacother 6:211–223
Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902
Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Eng J Med 362:1273–1281
Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in japan. Br J Cancer 103:469–474
Committee for Treatment Guideline for biliary tract cancer, Japanese Society for Hepato-Bilary-Pancreatic Surgery (2013) Treatment guideline for biliary tract cancer 2013, 2nd edn. Igakutosho shuppan, Tokyo
Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855
Sasaki T, Isayama H, Nakai Y et al (2010) Multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101–1107
Kanai M, Yoshimura K, Tsumura T et al (2011) A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67:1429–1434
Sasaki T, Isayama H, Nakai Y et al (2011) Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 29:1488–1489
Sasaki T, Isayama H, Nakai Y et al (2011) Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 67:847–853
Sasaki T, Isayama H, Takahara N et al (2013) A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy 59:106–111
Paule B, Herelle MO, Rage E et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105–110
Pino MS, Milella M, Gelibter A et al (2009) Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancer. Oncology 76:254–261
Lee S, Oh SY, Kim BG et al (2009) Second line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 32:348–352
Oh SY, Jeong CY, Hong SC et al (2011) Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 29:1066–1072
Therasse P, Arbuck SG, Einsenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Stallard N (2012) Optimal sample sizes for phase II and pilot studies. Stat Med 31:1031–1042
Sasaki T, Isayama H, Nakai Y et al (2013) A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 71:973–979
Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Cin Oncol 23:2332–2338
Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/ metastatic biliary tract carcinoma. Cancer 104:2753–2758
Riechelmann RP, Townsley CA, Chin SN et al (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307–1312
Iqbal S, Rankin C, Lenz HJ et al (2011) A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 68:1595–1602
Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a north central cancer treatment group phase II trial. Cancer 103:111–118
Aranyl I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464
Kyrochristos ID, Glantzounis GK, Ziogas DE et al (2017) From clinical standards to translating next-generation sequencing research into patient care improvement of hepatobiliary and pancreatic cancers. Int J Mol Sci. https://doi.org/10.3390/ijms18010180
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
R. Matsuyama, D. Morioka, R. Mori, S. Hiratani, Y. Yabushita, Y. Ota, T. Kumamoto, K. Taniguchi and I. Endo declare they have no conflict of interest to disclose.
Ethical approval
This study was conducted in accordance with the Helsinki Declaration and Good Clinical Practices and was approved by the institutional review board. The study has been registered with UMIN Clinical Trials Registry (no.: UMIN000007571).
Informed consent
We obtained written informed consent from all patients prior to participation.
Rights and permissions
About this article
Cite this article
Matsuyama, R., Morioka, D., Mori, R. et al. Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study. Cancer Chemother Pharmacol 81, 949–955 (2018). https://doi.org/10.1007/s00280-018-3566-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-018-3566-z